Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Entry into a Material Definitive Agreement
Item1.01.
| Entry into a Material Definitive Agreement. |
On December23, 2016, Achillion Pharmaceuticals, Inc. (the
Company) entered into an amendment (the Third Amendment) to the
Collaboration and License Agreement (License Agreement), dated
May19, 2015, by and between the Company and Janssen
Pharmaceuticals, Inc. (Janssen), which Third Amendment shall
become effective on December26, 2016.
The License Agreement provided for a $15.0 million payment by
Janssen to the Company for the Clinical Milestone Event under
Section8.3.1 of the License Agreement (the Milestone Payment).
The Third Amendment provides that the Milestone Payment shall be
due on dosing of the first patient in the OMEGA-1 Phase 2b study
of JNJ-4178 and payable by Janssen within thirty (30)days after
receipt by Janssen of an invoice from the Company.
The description of the terms and conditions of the Third
Amendment set forth herein is not complete and is qualified in
its entirety by reference to the full text of the Third Amendment
attached hereto as Exhibit 10.1 and incorporated herein by this
reference.
| Item9.01. | Financial Statements and Exhibits |
| (d) | Exhibits |
| 10.1 |
Third Amendment to Collaboration and License Agreement, dated as of December23, 2016, by and between Achillion Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc. |
About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Recent Trading Information
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed its last trading session 00.00 at 4.18 with 1,188,181 shares trading hands.
